CJS07的个人主页 - 老虎社区

CJS07

暂无个人介绍

IP属地：未知

7关注

1粉丝

0主题

0勋章

2021-09-10

Prizer,s share prize is too low despite its good performance

UK’s MHRA Grants Marketing Authorisation For Pfizer's Cibinqo For Adults And Adolescents With Moderate To Severe Atopic Dermatitis<blockquote>英国 MHRA 授予辉瑞公司 Cibinqo 用于中度至重度特应性皮炎成人和青少年的营销授权</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3575236051539340","uuid":"3575236051539340","gmtCreate":1612241500066,"gmtModify":1612241500066,"name":"CJS07","pinyin":"cjs07","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":7,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.07.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.13","exceedPercentage":"93.14%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.07%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":883890839,"gmtCreate":1631231240721,"gmtModify":1632883837595,"author":{"id":"3575236051539340","authorId":"3575236051539340","name":"CJS07","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575236051539340","authorIdStr":"3575236051539340"},"themes":[],"title":"","htmlText":"Prizer,s share prize is too low despite its good performance&nbsp;","listText":"Prizer,s share prize is too low despite its good performance&nbsp;","text":"Prizer,s share prize is too low despite its good performance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/883890839","repostId":"2166310922","repostType":2,"repost":{"id":"2166310922","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1631185740,"share":"https://www.laohunote.com/m/news/2166310922?lang=zh_CN&edition=full","pubTime":"2021-09-09 19:09","market":"hk","language":"en","title":"UK’s MHRA Grants Marketing Authorisation For Pfizer's Cibinqo For Adults And Adolescents With Moderate To Severe Atopic Dermatitis<blockquote>英国 MHRA 授予辉瑞公司 Cibinqo 用于中度至重度特应性皮炎成人和青少年的营销授权</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2166310922","media":"T-Reuters","summary":"Pfizer Inc :Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults ","content":"<p><html><body>Pfizer Inc <pfe.n>:Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults And Adolescents With Moderate To Severe Atopic Dermatitis.Pfizer Inc - Abrocitinib Is Licensed In Great Britain In Recommended Doses Of 100Mg And 200Mg..</pfe.n></p><p><blockquote><html><body>辉瑞公司<pfe.n>英国Mhra授予辉瑞Cibinqo上市许可®（Abrocitinib）用于患有中度至重度特应性皮炎的成人和青少年。辉瑞公司-Abrocitinib在英国获得许可，推荐剂量为100毫克和200毫克..</pfe.n></body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UK’s MHRA Grants Marketing Authorisation For Pfizer's Cibinqo For Adults And Adolescents With Moderate To Severe Atopic Dermatitis<blockquote>英国 MHRA 授予辉瑞公司 Cibinqo 用于中度至重度特应性皮炎成人和青少年的营销授权</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUK’s MHRA Grants Marketing Authorisation For Pfizer's Cibinqo For Adults And Adolescents With Moderate To Severe Atopic Dermatitis<blockquote>英国 MHRA 授予辉瑞公司 Cibinqo 用于中度至重度特应性皮炎成人和青少年的营销授权</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time smaller\">2021-09-09 19:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>Pfizer Inc <pfe.n>:Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults And Adolescents With Moderate To Severe Atopic Dermatitis.Pfizer Inc - Abrocitinib Is Licensed In Great Britain In Recommended Doses Of 100Mg And 200Mg..</pfe.n></p><p><blockquote><html><body>辉瑞公司<pfe.n>英国Mhra授予辉瑞Cibinqo上市许可®（Abrocitinib）用于患有中度至重度特应性皮炎的成人和青少年。辉瑞公司-Abrocitinib在英国获得许可，推荐剂量为100毫克和200毫克..</pfe.n></body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LHDX":"Lucira Health, Inc.","LABP":"Landos Biopharma, Inc.","CGEM":"Cullinan Therapeutics","SANA":"Sana Biotechnology, Inc.","PFE":"辉瑞"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166310922","content_text":"Pfizer Inc :Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults And Adolescents With Moderate To Severe Atopic Dermatitis.Pfizer Inc - Abrocitinib Is Licensed In Great Britain In Recommended Doses Of 100Mg And 200Mg..","news_type":1,"symbols_score_info":{"SANA":0.9,"CGEM":0.9,"LHDX":0.9,"LABP":0.9,"APR":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":333,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":883890839,"gmtCreate":1631231240721,"gmtModify":1632883837595,"author":{"id":"3575236051539340","authorId":"3575236051539340","name":"CJS07","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575236051539340","authorIdStr":"3575236051539340"},"themes":[],"title":"","htmlText":"Prizer,s share prize is too low despite its good performance&nbsp;","listText":"Prizer,s share prize is too low despite its good performance&nbsp;","text":"Prizer,s share prize is too low despite its good performance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/883890839","repostId":"2166310922","repostType":2,"repost":{"id":"2166310922","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1631185740,"share":"https://www.laohunote.com/m/news/2166310922?lang=zh_CN&edition=full","pubTime":"2021-09-09 19:09","market":"hk","language":"en","title":"UK’s MHRA Grants Marketing Authorisation For Pfizer's Cibinqo For Adults And Adolescents With Moderate To Severe Atopic Dermatitis<blockquote>英国 MHRA 授予辉瑞公司 Cibinqo 用于中度至重度特应性皮炎成人和青少年的营销授权</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2166310922","media":"T-Reuters","summary":"Pfizer Inc :Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults ","content":"<p><html><body>Pfizer Inc <pfe.n>:Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults And Adolescents With Moderate To Severe Atopic Dermatitis.Pfizer Inc - Abrocitinib Is Licensed In Great Britain In Recommended Doses Of 100Mg And 200Mg..</pfe.n></p><p><blockquote><html><body>辉瑞公司<pfe.n>英国Mhra授予辉瑞Cibinqo上市许可®（Abrocitinib）用于患有中度至重度特应性皮炎的成人和青少年。辉瑞公司-Abrocitinib在英国获得许可，推荐剂量为100毫克和200毫克..</pfe.n></body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UK’s MHRA Grants Marketing Authorisation For Pfizer's Cibinqo For Adults And Adolescents With Moderate To Severe Atopic Dermatitis<blockquote>英国 MHRA 授予辉瑞公司 Cibinqo 用于中度至重度特应性皮炎成人和青少年的营销授权</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUK’s MHRA Grants Marketing Authorisation For Pfizer's Cibinqo For Adults And Adolescents With Moderate To Severe Atopic Dermatitis<blockquote>英国 MHRA 授予辉瑞公司 Cibinqo 用于中度至重度特应性皮炎成人和青少年的营销授权</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time smaller\">2021-09-09 19:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>Pfizer Inc <pfe.n>:Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults And Adolescents With Moderate To Severe Atopic Dermatitis.Pfizer Inc - Abrocitinib Is Licensed In Great Britain In Recommended Doses Of 100Mg And 200Mg..</pfe.n></p><p><blockquote><html><body>辉瑞公司<pfe.n>英国Mhra授予辉瑞Cibinqo上市许可®（Abrocitinib）用于患有中度至重度特应性皮炎的成人和青少年。辉瑞公司-Abrocitinib在英国获得许可，推荐剂量为100毫克和200毫克..</pfe.n></body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LHDX":"Lucira Health, Inc.","LABP":"Landos Biopharma, Inc.","CGEM":"Cullinan Therapeutics","SANA":"Sana Biotechnology, Inc.","PFE":"辉瑞"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166310922","content_text":"Pfizer Inc :Uk’S Mhra Grants Marketing Authorisation For Pfizer’S Cibinqo® (Abrocitinib) For Adults And Adolescents With Moderate To Severe Atopic Dermatitis.Pfizer Inc - Abrocitinib Is Licensed In Great Britain In Recommended Doses Of 100Mg And 200Mg..","news_type":1,"symbols_score_info":{"SANA":0.9,"CGEM":0.9,"LHDX":0.9,"LABP":0.9,"APR":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":333,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}